The evolving treatment landscape of advanced urothelial carcinoma.,Current Opinion in Oncology

当前位置： X-MOL 学术 › Curr. Opin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The evolving treatment landscape of advanced urothelial carcinoma.
Current Opinion in Oncology ( IF 3.4 ) Pub Date : 2021-4-6 , DOI: 10.1097/cco.0000000000000722
Alexander Y Andreev-Drakhlin ₁ , Goar Egoryan ₂ , Amishi Y Shah _{1,

3} , Pavlos Msaouel _{1,

3} , Omar Alhalabi _{1,

3} , Jianjun Gao _{1,

3}

Affiliation

Bladder cancer is the 10th most common cancer in the world and the 6th most common cancer among men. In the past few years, several new agents have been approved for the treatment of urothelial tumors. In this paper, we review the evolving treatment landscape of advanced urothelial carcinoma (UC).

中文翻译：